Back to results
US 12,551,552 B2Granted
Antigenic glycoprotein E polypeptides, compositions, and methods of use thereof
AssigneeMerck Sharp & Dohme Corp.
InventorsArthur Fridman, Jennifer Dawn Galli, Dai Wang, Lan Zhang
Life of this patent
Estimating the term…
Abstract
The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Virus (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain.
Claims15
An isolated polypeptide comprising the mature amino acid sequence of any one of SEQ ID NOs:
- 12-27, or a variant thereof, wherein the variant of SEQ ID NO:
- 12 does not vary any of positions 337-344, wherein the variant of SEQ ID NO:
- 13 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 14 does not vary any of positions 337-339, wherein the variant of SEQ ID NO:
- 15 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 16 does not vary any of positions 337-339, wherein the variant of SEQ ID NO:
- 17 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 18 does not vary any of positions 337-338, wherein the variant of SEQ ID NO:
- 19 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 20 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 21 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 22 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 23 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 24 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 25 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 26 does not vary any of positions 245, 317, or 319, or wherein the variant of SEQ ID NO:
- 27 does not vary any of positions 245, 317, or 319, and wherein the variant amino acid sequence of the isolated polypeptide has 95-99% homology to the amino acid sequence of SEQ ID NO:
- 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27.
15 more elements
An isolated polypeptide, comprising the amino acid sequence of SEQ ID NOs:
- 12, 20, 24, or 26, or a variant thereof, wherein the variant of SEQ ID NO:
- 12 does not vary any of positions 337-344, wherein the variant of SEQ ID NO:
- 20 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 24 does not vary any of positions 245, 317, or 319, or wherein the variant of SEQ ID NO:
- 26 does not vary any of positions 245, 317, or 319, and wherein the variant amino acid sequence of the isolated polypeptide has 95-99% homology to the amino acid sequence of SEQ ID NO:
- 12, 20, 24, or 26.
3 more elements
An isolated nucleic acid comprising the nucleotide sequence of any one of SEQ ID NOs:
- 29-44, or a variant thereof, wherein the variant of SEQ ID NO:
- 29 comprises nucleotides at positions 1009-1032 that encode amino acids at positions 337-344 of SEQ ID NO:
- 12, wherein the variant of SEQ ID NO:
- 30 comprises nucleotides at positions 1009-1020 that encode amino acids at positions 337-340 of SEQ ID NO:
- 13, wherein the variant of SEQ ID NO:
- 31 comprises nucleotides at positions 1009-1017 that encode amino acids at positions 337-339 of SEQ ID NO:
- 14, wherein the variant of SEQ ID NO:
- 32 comprises nucleotides at positions 1009-1020 that encode amino acids at positions 337-340 of SEQ ID NO:
- 15, wherein the variant of SEQ ID NO:
- 33 comprises nucleotides at positions 1009-1017 that encode amino acids at positions 337-339 of SEQ ID NO:
- 16, wherein the variant of SEQ ID NO:
- 34 comprises nucleotides at positions 1009-1020 that encode amino acids at positions 337-340 of SEQ ID NO:
- 17, wherein the variant of SEQ ID NO:
- 35 comprises nucleotides at positions 1009-1014 that encode amino acids at positions 337-338 of SEQ ID NO:
- 18, wherein the variant of SEQ ID NO:
- 36 comprises nucleotides at positions 1009-1020 that encode amino acids at positions 337-340 of SEQ ID NO:
- 19, wherein the variant of SEQ ID NO:
- 37 comprises nucleotides at positions 1009-1020 that encode amino acids at positions 337-340 of SEQ ID NO:
- 20, wherein the variant of SEQ ID NO:
- 38 comprises nucleotides at positions 733-735 that encode residue 245 of SEQ ID NO:
- 21, wherein the variant of SEQ ID NO:
- 39 comprises nucleotides at positions 949-951 that encode residue 317 of SEQ ID NO:
- 22, wherein the variant of SEQ ID NO:
- 40 comprises nucleotides at positions 955-957 that encode residue 319 of SEQ ID NO:
- 23, wherein the variant of SEQ ID NO:
- 41 comprises nucleotides at positions 733-735 and 949-951 that encode amino acids at positions 245 and 317, respectively, of SEQ ID NO:
- 24, wherein the variant of SEQ ID NO:
- 42 comprises nucleotides at positions 733-735 and 955-957 that encode amino acids at positions 245 and 319, respectively, of SEQ ID NO:
- 25, wherein the variant of SEQ ID NO:
- 43 comprises nucleotides at positions 949-951 and 955-957 that encode amino acids at positions 317 and 319, respectively, of SEQ ID NO:
- 26, or wherein the variant of SEQ ID NO:
- 44 comprises nucleotides at positions 733-735, 949-951, and 955-957 that encode amino acids at positions 245, 317, and 319, respectively, of SEQ ID NO:
- 27, and wherein the variant nucleic acid sequence of the isolated nucleic acid has 95-99% homology to the nucleic acid sequence of SEQ ID NOs:
- 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44.
31 more elements
A Herpes Simplex Virus (HSV) vaccine comprising an isolated antigenic polypeptide, the isolated antigenic polypeptide comprising the mature amino acid sequence of any one of SEQ ID NOs:
- 12-27, or a variant thereof, wherein the variant of SEQ ID NO:
- 12 does not vary any of positions 337-344, wherein the variant of SEQ ID NO:
- 13 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 14 does not vary any of positions 337-339, wherein the variant of SEQ ID NO:
- 15 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 16 does not vary any of positions 337-339, wherein the variant of SEQ ID NO:
- 17 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 18 does not vary any of positions 337-338, wherein the variant of SEQ ID NO:
- 19 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 20 does not vary any of positions 337-340, wherein the variant of SEQ ID NO:
- 21 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 22 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 23 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 24 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 25 does not vary any of positions 245, 317, or 319, wherein the variant of SEQ ID NO:
- 26 does not vary any of positions 245, 317, or 319, or wherein the variant of SEQ ID NO:
- 27 does not vary any of positions 245, 317, or 319, and wherein the variant isolated antigenic polypeptide has 95-99% homology to the amino acid sequence of SEQ ID NOs:
- 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27.
15 more elements
Dependencies are inferred from the claim text.